查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
基於EV的液態切片的全球市場 (2023-2032)：按服務細分、工作流程、樣本類型、最終用戶、技術和地區分類的分析、預測和競爭格局
市場調查報告書
商品編碼
1318829

基於EV的液態切片的全球市場 (2023-2032)：按服務細分、工作流程、樣本類型、最終用戶、技術和地區分類的分析、預測和競爭格局

Global EV-Based Liquid Biopsy Market - A Global and Regional Analysis: Focus on Offering, Workflow, Sample Type, End User, Technology, Regional Analysis, and Competitive Landscape - Analysis and Forecast, 2023-2032
出版日期: | 出版商: BIS Research | 英文 166 Pages | 商品交期: 1-5個工作天內

價格
主要市場統計資料
開始年份 2023年
預測年份 2032
開始年的市場規模 9009萬美元（2023年）
市場規模預測 4.5553 億美元（2032年）
年複合成長率（%）： 19.73%

基於EV的液態切片：全球市場概述

預計到2032年，全球基於EV的液態切片市場規模將達到 4.5553 億美元，預測期內年複合成長率為 19.73%，而2022年為 7822 萬美元。

市場的成長預計將由持續的技術進步、醫療保健提供者越來越多的採用以及對個性化醫療的日益關注來推動。

市場生命週期階段

全球基於EV的液態切片市場正處於發展階段，學術研究和市場產品批准不斷增加。此外，基於EV的液態切片在個性化醫療和精準腫瘤學中的日益成長的用途預計也將推動市場的進一步擴張。

從提供的細分市場來看，試劑盒和檢測細分市場將在2022年佔據市場主導地位。隔離試劑盒、檢測方法和配件的採用增加有助於該細分市場的成長。各種外泌體和 EV 分離套件用於執行各種程序和液態切片。

從技術角度來看，分離行業將在2022年佔據市場主導地位。在分離技術中，沉澱已成為最常用的技術。從工作流程來看，樣品製備領域將在2022年引領市場。按最終用戶分類，學術和研究領域同年佔據了最大的市場佔有率。這些機構主要從事生物標記鑑定、藥物開發和靶向細胞分析等研究活動。

按地區分類，北美地區預計將在2022年佔據市場主導地位，並在整個預測期內保持主導地位。另一方面，擁有多個新興經濟體的亞太地區預計在預測期內成長率最高，年複合成長率為21.64%。

主要公司簡介

  • Abcam plc
  • Bio-Techne Corporation
  • Horiba Ltd.
  • Qiagen NV
  • Thermo Fisher Scientific, Inc.
  • Malvern Panalytical Ltd
  • Lonza Group AG
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Takara Bio Inc.
  • Norgen Biotek Corp.

本報告考察了全球基於EV的液態切片市場，提供市場定義和概述、EV 隔離和分析方法、監管和保險給付環境、市場影響因素和市場機會分析以及市場規模趨勢和預測。按類別詳細分析以及地區、競爭狀況、主要公司簡介等。

目錄

第1章 定義

第2章 調查範圍

第3章 調查方法

第4章 市場概況

第5章 EV 分離與分析技術

  • 概述
  • 分離技術
  • 分析方法

第6章 行業考察

  • 概述
  • 美國法律要求
  • 歐洲法律要求和框架
  • 亞太地區的法律要求和框架
  • 保險給付情境

第7章 市場動態

  • 概述
  • 影響分析
  • 市場促進因素
  • 市場抑制因素
  • 市場機會

第8章 競爭格局

  • 競爭格局概覽
  • 市場佔有率分析
  • 成長佔有率分析

第9章 全球基於電動汽車的液態切片市場，按產品細分

  • 試劑盒檢測
  • 服務
  • 設備

第10章 全球基於EV的液態切片市場（按工作流程）

  • 樣品製備
  • 順序
  • 資料分析

第11章 全球基於EV的液態切片市場（按技術）

  • 絕緣技術
    • 沉澱
    • 超速離心
    • 色譜法
  • 分析技術
    • NGS
    • PCR
    • 流式細胞儀

第12章 全球基於EV的液態切片市場（按樣本類型）

  • 血
  • 尿
  • 唾液
  • 其他

第13章 全球基於EV的液態切片市場（按最終用戶）

  • 學術研究所
  • 製藥和生物技術公司
  • 臨床實驗室

第14章 全球基於EV的液態切片市場（按地區）

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲/中東
  • 其他地區

第15章 公司簡介

  • 公司簡介
Product Code: BHP1400SA

“Global EV-Based Liquid Biopsy Market to Reach $455.53 Million by 2032.”

Global EV-Based Liquid Biopsy Market Overview

The global EV-based liquid biopsy market was valued at $78.22 million in 2022 and is anticipated to reach $455.53 million by 2032, witnessing a CAGR of 19.73% during the forecast period 2023-2032. The global EV-based liquid biopsy market is expected to be driven by ongoing technological advancements, increasing adoption by healthcare providers, and a growing focus on personalized medicine.

KEY MARKET STATISTICS
Start Year:2023
Forecast Year2032
Start Value$90.09 Million in 2023
Forecast Value$455.53 Million by 2032
CAGR %19.73%

Market Lifecycle Stage

The global EV-based liquid biopsy market is in progressing phase, which can be attributed to the increase in academic research and approval of products in the market. Furthermore, the expanding applications of EV-based liquid biopsy in personalized medicine and precision oncology are projected to drive further market expansion.

Impact

The adoption of EV-based liquid biopsy has revolutionized disease diagnosis and monitoring, offering numerous benefits over traditional biopsy methods. Its non-invasiveness, real-time monitoring capabilities, and potential for early disease detection have transformed the field of healthcare diagnostics. By providing a less invasive and more accessible method for detecting and monitoring diseases, particularly cancer, EV-based liquid biopsy has improved patient experiences, reduced healthcare costs, and enhanced overall healthcare outcomes. In addition, the entry of several established players, such as Thermo Fisher Scientific Inc., QIAGEN N.V., and Bio-Techne Corporation, is expected to aid the market growth.

Furthermore, the growth of the EV-based liquid biopsy market has stimulated research and development activities, fostered collaborations between industry players and academic institutions, and generated economic opportunities.

Market Segmentation:

Segmentation 1: by Offering

  • Kits and Assays
  • Services
  • Instruments

Kits and Assays Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Offering)

Based on offering, the kits and assays segment dominated the global EV-based liquid biopsy market in FY2022. The increasing adoption of isolation kits, assays, and accessories contributed to the prominence of this segment. Various exosome and EV isolation kits are being used to carry out several procedures and liquid biopsy tests.

Segmentation 2: by Technology

  • Isolation
  • Analysis

Isolation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Technology)

Based on technology, the isolation segment dominated the global EV-based liquid biopsy market in FY2022. Under isolation technology, precipitation emerged as the most common technology used.

Segmentation 3: by Workflow

  • Sample Preparation
  • Sequencing
  • Data Analysis

Sample Preparation Segment to Dominate the Global EV-Based Liquid Biopsy Market (by Workflow)

Based on workflow, the EV-based liquid biopsy market was dominated by the sample preparation segment in FY2022. The sample preparation or pre-analytical phase in the EV-based liquid biopsy workflow includes specimen collection, stabilization, transport, enrichment, processing, isolation, and quality assessment of the analyte.

Segmentation 4: by End User

  • Academic and Research Institutes
  • Clinical Laboratories
  • Pharmaceutical and Biotechnology Companies

Academic and Research Institutes Segment to Dominate the Global EV-Based Liquid Biopsy Market (by End User)

Based on end user, academic and research segment accounted for the largest share of the global EV-based liquid biopsy market in FY2022. Academic and research institutes play a vital role in the adoption of EV-based liquid biopsy methods, serving as essential facilities for both companies and independent academic research. These institutions are primarily engaged in research activities aimed at identifying biomarkers, developing drugs, and conducting cell analysis to acquire targets.

Segmentation 5: by Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America and Middle East
  • Rest-of-the-World

In 2022, the North America region dominated the global EV-based liquid biopsy market, and it is expected to hold its dominance throughout the forecast period 2023-2032. However, the Asia-Pacific (APAC) region, constituting several emerging economies, is expected to register the highest CAGR of 21.64% in the market during the forecast period 2023-2032.

Demand - Drivers, Restraints, and Opportunities

Market Demand Drivers:

  • Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
  • Amplified Funding and Dedicated Research Efforts
  • Increasing Prevalence of Cancers

Market Restraints:

  • Lack of Standardized EV Isolation and Characterization Protocols
  • Lack of Precise EV Subtype Classification and Biomarkers Validation

Market Opportunities:

  • Advancements in EV-Based Liquid Biopsy Technologies
  • Development of New EV-Based Biomarkers
  • Approved Products in the Market

How can this report add value to an organization?

  • Workflow/Innovation Strategy: The EV-based liquid biopsy market (by offering) has been segmented into kits and assays, instruments, and services. Moreover, the study provides the reader with a detailed understanding of the different types of technologies, end-users, and sample types used in these tests.
  • Growth/Marketing Strategy: EV-based liquid biopsy has tremendous growth potential due to its ability to revolutionize non-invasive cancer detection and monitoring. By analyzing the cargo of Evs, researchers can gain insights into the presence, type, and characteristics of tumors without directly accessing the tumor site.
  • Competitive Strategy: Key players in the EV-based liquid biopsy market have been analyzed and profiled in the study, including manufacturers. Moreover, a detailed competitive benchmarking of the players operating in the EV-based liquid biopsy market has been done to help the reader understand how players stack against each other, presenting a clear market landscape.

Key Market Players and Competition Synopsis

EV-based liquid biopsy refers to the use of extracellular vesicles (Evs) as a non-invasive diagnostic tool for detecting and monitoring various diseases, including cancer. The global EV-based liquid biopsy market has experienced substantial growth driven by technological advancements, rising demand for non-invasive diagnostics, and the global increase in cancer prevalence.

Key Companies Profiled:

  • Abcam plc
  • Bio-Techne Corporation
  • Horiba Ltd.
  • Qiagen N.V.
  • Thermo Fisher Scientific, Inc.
  • Malvern Panalytical Ltd
  • Lonza Group AG
  • Revvity, Inc. (PerkinElmer, Inc.)
  • Takara Bio Inc.
  • Norgen Biotek Corp.

Table of Contents

1 Definition

  • 1.1 Inclusion and Exclusion Criteria

2 Research Scope

  • 2.1 Target Audience
  • 2.2 Key Questions Answered in the Report:

3 Research Methodology

  • 3.1 Global EV-Based Liquid Biopsy Market: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary Data Sources
  • 3.4 Market Estimation Model
  • 3.5 Criteria for Company Profiling

4 Markets Overview

  • 4.1 Market Introduction
  • 4.2 Current and Future State of EV-Based Liquid Biopsy in Industries
  • 4.3 Current Market Size and Growth Potential, $Million, 2022-2032
  • 4.4 COVID-19 Impact on Global EV-based Liquid Biopsy Market
    • 4.4.1 Impact on Operations
    • 4.4.2 COVID-19 Impact: Current Scenario of the Market

5 Methods of EV Isolation and Analysis

  • 5.1 Overview
    • 5.1.1 Evs Introduction
  • 5.2 Isolation Methods
    • 5.2.1 EV Isolation Techniques Utilizing Ultracentrifugation Methods
      • 5.2.1.1 Differential Ultracentrifugation
      • 5.2.1.2 Density Gradient Centrifugation
      • 5.2.1.3 Moving Zone or Rate-Zonal Centrifugation
      • 5.2.1.4 Isopycnic Centrifugation
    • 5.2.2 EV Isolation Techniques Utilizing Size-Based Methods
      • 5.2.2.1 Ultrafiltration
      • 5.2.2.2 Sequential Filtration
      • 5.2.2.3 Size Exclusion Chromatography (SEC)
      • 5.2.2.4 Flow Field-Flow Fractionation (FFFF)
      • 5.2.2.5 Hydrostatic Filtration Dialysis (HFD)
    • 5.2.3 EV Isolation Techniques Utilizing Immunoaffinity Methods
      • 5.2.3.1 Enzyme-Linked Immunosorbent Assay (ELISA)
      • 5.2.3.2 Magneto-Immunoprecipitation
    • 5.2.4 EV Isolation Techniques Utilizing Precipitation Methods
      • 5.2.4.1 Polyethylene Glycol (PEG) Precipitation
      • 5.2.4.2 Lectin Induced Agglutination
    • 5.2.5 EV Isolation Techniques Utilizing Microfluidic Technology
    • 5.2.6 EV Isolation Techniques Utilizing Commercial Kits
    • 5.2.7 Advantages and Disadvantages of the EV Isolation Methods
    • 5.2.8 Novel Approaches for Exosome Isolation
  • 5.3 Analysis Methods
    • 5.3.1 Advantages and Disadvantages of Analysis Methods for Evs

6 Industry Insights

  • 6.1 Overview
  • 6.2 Legal Requirements in the U.S.
  • 6.3 Legal Requirements and Frameworks in Europe
  • 6.4 Legal Requirements and Frameworks in Asia-Pacific
  • 6.5 Reimbursement Scenario

7 Market Dynamics

  • 7.1 Overview
  • 7.2 Impact Analysis
  • 7.3 Market Drivers
    • 7.3.1 Abundance and Remarkable Stability of Exosomes Compared to CfDNA or CTCs
    • 7.3.2 Amplified Funding and Dedicated Research Efforts
    • 7.3.3 Rising Prevalence of Cancers
  • 7.4 Market Restraints
    • 7.4.1 Lack of Standardized EV Isolation and Characterization Protocols
    • 7.4.2 Lack of Precise EV Subtype Classification and Biomarkers Validation
  • 7.5 Market Opportunities
    • 7.5.1 Advancements in EV-Based Liquid Biopsy Technologies
    • 7.5.2 Development of New EV-Based Biomarkers
    • 7.5.3 Approved Products in the Market

8 Competitive Landscape

  • 8.1 Competitive Landscape Overview
    • 8.1.1 Key Developments
    • 8.1.2 Product Launches and Expansion Activities
    • 8.1.3 Merger and Acquisition Activities
    • 8.1.4 Synergistic Activities
    • 8.1.5 License and Agreement Activities
    • 8.1.6 Other Activities
  • 8.2 Market Share Analysis (2022)
  • 8.3 Growth-Share Analysis (2021-2022)
    • 8.3.1 Growth-Share Analysis (by Company)

9 Global EV-Based Liquid Biopsy Market (by Offering),$Million, 2022-2032

  • 9.1 Overview
  • 9.2 Kits and Assays
  • 9.3 Services
  • 9.4 Instruments

10 Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022-2032

  • 10.1 Overview
    • 10.1.1 Sample Preparation
    • 10.1.2 Sequencing
    • 10.1.3 Data Analysis

11 Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022-2032

  • 11.1 Overview
  • 11.2 Isolation Technologies
    • 11.2.1 Precipitation
    • 11.2.2 Ultracentrifugation
    • 11.2.3 Chromatography
  • 11.3 Analysis Technologies
    • 11.3.1 NGS
    • 11.3.2 PCR
    • 11.3.3 Flow Cytometry

12 Global EV-Based Liquid Biopsy Market (by Sample Type), $Million, 2022-2032

  • 12.1 Overview
    • 12.1.1 Blood
    • 12.1.2 Urine
    • 12.1.3 Saliva
    • 12.1.4 Other Biofluids

13 Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022-2032

  • 13.1 Overview
  • 13.2 Academic and Research Institutes
  • 13.3 Pharmaceutical and Biotechnology Companies
  • 13.4 Clinical Laboratories

14 Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032

  • 14.1 Overview
  • 14.2 North America
    • 14.2.1 U.S.
    • 14.2.2 Canada
  • 14.3 Europe
    • 14.3.1 Germany
    • 14.3.2 U.K.
    • 14.3.3 France
    • 14.3.4 Italy
    • 14.3.5 Spain
    • 14.3.6 Rest-of-Europe
  • 14.4 Asia-Pacific
    • 14.4.1 China
    • 14.4.2 Japan
    • 14.4.3 India
    • 14.4.4 South Korea
    • 14.4.5 Australia
    • 14.4.6 Singapore
    • 14.4.7 Rest-of-Asia-Pacific
  • 14.5 Latin America and Middle East
    • 14.5.1 Brazil
    • 14.5.2 Mexico
    • 14.5.3 Saudi Arabia
    • 14.5.4 Rest-of-Latin America and Middle East
  • 14.6 Rest-of-the-World

15 Company Profiles

  • 15.1 Company Overview
    • 15.1.1 Abcam plc
      • 15.1.1.1 Company Overview
      • 15.1.1.2 Role of Abcam plc in the Global EV-Based Liquid Biopsy Market
      • 15.1.1.3 Major Products: Key Specifications
      • 15.1.1.4 Key Competitors
      • 15.1.1.5 Analyst Perspective
    • 15.1.2 Bio-Techne Corporation
      • 15.1.2.1 Company Overview
      • 15.1.2.2 Role of Bio-Techne Corporation in the Global EV-Based Liquid Biopsy Market
      • 15.1.2.3 Major Products: Key Specifications
      • 15.1.2.4 Key Competitors
      • 15.1.2.5 Analyst Perspective
    • 15.1.3 Horiba Ltd.
      • 15.1.3.1 Company Overview
      • 15.1.3.2 Role of Horiba Ltd. in the Global EV-Based Liquid Biopsy Market
      • 15.1.3.3 Major Products: Key Specifications
      • 15.1.3.4 Key Competitors
      • 15.1.3.5 Analyst Perspective
    • 15.1.4 Qiagen N.V.
      • 15.1.4.1 Company Overview
      • 15.1.4.2 Role of Qiagen N.V. in the Global EV-Based Liquid Biopsy Market
      • 15.1.4.3 Major Products: Key Specifications
      • 15.1.4.4 Key Competitors
      • 15.1.4.5 Analyst Perspective
    • 15.1.5 Thermo Fisher Scientific, Inc.
      • 15.1.5.1 Company Overview
      • 15.1.5.2 Role of Thermo Fisher Scientific, Inc. in the Global EV-Based Liquid Biopsy Market
      • 15.1.5.3 Major Products: Key Specifications
      • 15.1.5.4 Key Competitors
      • 15.1.5.5 Analyst Perspective
    • 15.1.6 Malvern Panalytical Ltd
      • 15.1.6.1 Company Overview
      • 15.1.6.2 Role of Malvern Panalytical Ltd in the Global EV-Based Liquid Biopsy Market
      • 15.1.6.3 Major Products: Key Specifications
      • 15.1.6.4 Key Competitors
      • 15.1.6.5 Analyst Perspective
    • 15.1.7 Lonza Group AG
      • 15.1.7.1 Company Overview
      • 15.1.7.2 Role of Lonza Group AG in the Global EV-Based Liquid Biopsy Market
      • 15.1.7.3 Major Products: Key Specifications
      • 15.1.7.4 Key Competitors
      • 15.1.7.5 Analyst Perspective
    • 15.1.8 Revvity, Inc. (PerkinElmer, Inc.)
      • 15.1.8.1 Company Overview
      • 15.1.8.2 Role of Revvity, Inc. (PerkinElmer Inc.) in the Global EV-Based Liquid Biopsy Market
      • 15.1.8.3 Major Products: Key Specifications
      • 15.1.8.4 Key Competitors
      • 15.1.8.5 Analyst Perspective
    • 15.1.9 Takara Bio Inc.
      • 15.1.9.1 Company Overview
      • 15.1.9.2 Role of Takara Bio Inc. in the Global EV-Based Liquid Biopsy Market
      • 15.1.9.3 Major Products: Key Specifications
      • 15.1.9.4 Key Competitors
      • 15.1.9.5 Analyst Perspective
    • 15.1.10 Norgen Biotek Corp.
      • 15.1.10.1 Company Overview
      • 15.1.10.2 Role of Norgen Biotek Corp. in the Global EV-Based Liquid Biopsy Market
      • 15.1.10.3 Major Products: Key Specifications
      • 15.1.10.4 Key Competitors
      • 15.1.10.5 Analyst Perspective
    • 15.1.11 Emerging Companies
      • 15.1.11.1 Mursla Bio
      • 15.1.11.2 Nanostics Inc.
      • 15.1.11.3 Mercy BioAnalytics, Inc.
      • 15.1.11.4 Clara Diagnostics, Inc. (Clara Biotech)

List of Figures

  • Figure 1: Global EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
  • Figure 2: Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
  • Figure 3: Global EV-Based Liquid Biopsy Market (by Region), 2022
  • Figure 4: Global EV-Based Liquid Biopsy Market Segmentation
  • Figure 5: Global EV-Based Liquid Biopsy Market Regional Segmentation
  • Figure 6: Global EV-Based Liquid Biopsy Market Methodology
  • Figure 7: Primary Research Methodology
  • Figure 8: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 9: Top-Down Approach (Segment-Wise Analysis)
  • Figure 10: Global EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 11: Subtypes of Evs
  • Figure 12: Methods of EV-Isolation from Biofluids
  • Figure 13: Workflow of Differential Ultracentrifugation for Exosome Isolation
  • Figure 14: Methods of EV-Analysis
  • Figure 15: Global EV-Based Liquid Biopsy Market - Market Dynamics
  • Figure 16: Structure of Evs Enveloped by Protective Lipid Membrane
  • Figure 17: Number of Research Publications on Exosomes, 2015-2021
  • Figure 18: Share of New Cancer Cases, 2020
  • Figure 19: Number of Cancer Cases, 2020
  • Figure 20: Currently Investigated Circulating Biomarkers Associated with Evs
  • Figure 21: Share of Key Developments and Strategies, January 2019-June 2023
  • Figure 22: Share of Product Launch and Expansion Activities (by Company), January 2019-June 2023
  • Figure 23: Share of Synergistic Activities (by Company), January 2019-June 2023
  • Figure 24: Share of Other Activities (by Company), January 2019-June 2023
  • Figure 25: Market Share Analysis for Global EV-Based Liquid Biopsy Market, 2022
  • Figure 26: Growth-Share Analysis for Global EV-Based Liquid Biopsy Market (by Company), 2021-2022
  • Figure 27: Global EV-Based Liquid Biopsy Market (by Offering), $Million, 2022-2032
  • Figure 28: Global EV-Based Liquid Biopsy Market (Kits and Assays), $Million, 2022-2032
  • Figure 29: Global EV-Based Liquid Biopsy Market (Services), $Million, 2022-2032
  • Figure 30: Global EV-Based Liquid Biopsy Market (Instruments), $Million, 2022-2032
  • Figure 31: Global EV-Based Liquid Biopsy Market (by Workflow), $Million, 2022 and 2032
  • Figure 32: Global EV-Based Liquid Biopsy Market (Sample Preparation), $Million, 2022-2032
  • Figure 33: Global EV-Based Liquid Biopsy Market (Sequencing), $Million, 2022-2032
  • Figure 34: Global EV-Based Liquid Biopsy Market (Data Analysis), $Million, 2022-2032
  • Figure 35: Global EV-Based Liquid Biopsy Market (by Technology)
  • Figure 36: Global EV-Based Liquid Biopsy Market (by Technology), $Million, 2022 and 2032
  • Figure 37: Global EV-Based Liquid Biopsy Market (Isolation Technologies), $Million, 2022-2032
  • Figure 38: Global EV-Based Liquid Biopsy Market (Precipitation), $Million, 2022-2032
  • Figure 39: Global EV-Based Liquid Biopsy Market (Ultracentrifugation), $Million, 2022-2032
  • Figure 40: Global EV-Based Liquid Biopsy Market (Chromatography), $Million, 2022-2032
  • Figure 41: Global EV-Based Liquid Biopsy Market (Analysis Technologies), $Million, 2022-2032
  • Figure 42: Global EV-Based Liquid Biopsy Market (NGS), $Million, 2022-2032
  • Figure 43: Global EV-Based Liquid Biopsy Market (PCR), $Million, 2022-2032
  • Figure 44: Global EV-Based Liquid Biopsy Market (Flow Cytometry), $Million, 2022-2032
  • Figure 45: Global EV-Based Liquid Biopsy Market (by Sample Type)
  • Figure 46: Global EV-Liquid Biopsy Market (by Sample Type), $Million, 2022 and 2032
  • Figure 47: Global EV-Based Liquid Biopsy Market (Blood), $Million, 2022-2032
  • Figure 48: Global EV-Based Liquid Biopsy Market (Urine), $Million, 2022-2032
  • Figure 49: Global EV-Based Liquid Biopsy Market (Saliva), $Million, 2022-2032
  • Figure 50: Global EV-Based Liquid Biopsy Market (Other Biofluids), $Million, 2022-2032
  • Figure 51: Global EV-Based Liquid Biopsy Market (by End User)
  • Figure 52: Global EV-Based Liquid Biopsy Market (by End User), $Million, 2022 and 2032
  • Figure 53: Global EV-Based Liquid Biopsy Market (Academic and Research Institutes), $Million, 2022-2032
  • Figure 54: Global EV-Based Liquid Biopsy Market (Pharmaceutical and Biotechnology Companies), $Million, 2022-2032
  • Figure 55: Global EV-Based Liquid Biopsy Market (Clinical Laboratories), $Million, 2022-2032
  • Figure 56: Global EV-Based Liquid Biopsy Market Snapshot (by Region)
  • Figure 57: Global EV-Based Liquid Biopsy Market (by Region), $Million, 2022-2032
  • Figure 58: North America EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 59: North America: Market Dynamics
  • Figure 60: North America EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 61: U.S. EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 62: Canada EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 63: Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 64: Europe: Market Dynamics
  • Figure 65: Europe EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 66: Germany EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 67: U.K. EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 68: France EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 69: Italy EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 70: Spain EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 71: Rest-of-Europe EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 72: Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 73: Asia-Pacific: Market Dynamics
  • Figure 74: Asia-Pacific EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 75: China EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 76: Japan EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 77: India EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 78: South Korea EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 79: Australia EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 80: Singapore EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 81: Rest-of-Asia-Pacific EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 82: Latin America and Middle East EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 83: Latin America and Middle East: Market Dynamics
  • Figure 84: Latin America and Middle East EV-Based Liquid Biopsy Market (by Country), $Million, 2022-2032
  • Figure 85: Brazil EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 86: Mexico EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 87: Saudi Arabia EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 88: Rest-of-Latin America and Middle East EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 89: Rest-of-the-World EV-Based Liquid Biopsy Market, $Million, 2022-2032
  • Figure 90: Total Number of Companies Profiled
  • Figure 91: Abcam plc: Product Portfolio
  • Figure 92: Bio-Techne Corporation: Product Portfolio
  • Figure 93: Horiba Ltd.: Product Portfolio
  • Figure 94: Qiagen N.V.: Product Portfolio
  • Figure 95: Thermo Fisher Scientific, Inc.: Product Portfolio
  • Figure 96: Malvern Panalytical Ltd: Product Portfolio
  • Figure 97: Lonza Group AG: Product Portfolio
  • Figure 98: Revvity, Inc. (PerkinElmer Inc.): Product Portfolio
  • Figure 99: Takara Bio Inc.: Product Portfolio
  • Figure 100: Norgen Biotek Corp.: Product Portfolio

List of Tables

  • Table 1: Current and Future State of EV-Based Liquid Biopsy in Industries
  • Table 2: Example of Few Commercial Kits Available for EV Isolation
  • Table 3: Advantages and Disadvantages of the EV Isolation Methods
  • Table 4: Emerging Methods for the Isolation of Exosomes
  • Table 5: Advantages and Disadvantages of Analysis Methods for Evs
  • Table 6: Legal Requirements in the U.S.
  • Table 7: Legal Landscape for EV-Based Liquid Biopsies in Europe
  • Table 8: Size and Densities of Evs and Various Lipoproteins
  • Table 9: Technological Advancements in EV-Based Liquid Biopsy